Paul Orchard
Distinguished in Osteosclerosis Autosomal Dominant

Dr. Paul Orchard

Hematology | Oncology
University Of Minnesota Masonic Children's Hospital
420 Delaware St SE, 
Minneapolis, MN 
38 Years of Experience
Distinguished in Osteosclerosis Autosomal Dominant
University Of Minnesota Masonic Children's Hospital
420 Delaware St SE, 
Minneapolis, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Paul Orchard is a Pediatric Hematologist Oncologist and a Pediatrics specialist in Minneapolis, Minnesota. He has been an author on 166 peer reviewed articles and participated in 18 clinical trials in the past 15 years. He is licensed to treat patients in MN.

Dr. Orchard is rated as a Distinguished provider by MediFind in the treatment of Osteosclerosis Autosomal Dominant. His top areas of expertise are Adrenoleukodystrophy (ALD), Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), Mucopolysaccharidoses (MPS), Bone Marrow Transplant, and Osteotomy.

His clinical research consists of co-authoring 208 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 13 articles and participated in 1 clinical trial in the study of Osteosclerosis Autosomal Dominant.

Residency
University of Wisconsin Hospital
Specialties
Hematology
Oncology
Licenses
Pediatric Hematology-Oncology in MN
Board Certifications
Pediatrics
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
HealthPartners
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sanford Health
  • HMO
  • PPO

Locations

University of Minnesota Masonic Children's Hospital
420 Delaware St SE, Minneapolis, MN 55455

Additional Areas of Focus

Dr. Orchard has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG
MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG
Enrollment Status: Active_not_recruiting
Publish Date: January 07, 2026
Intervention Type: Drug, Biological
Study Drugs: Fludarabine, Busulfan, Anti-Thymocyte Globulin, Thiotepa, Rituximab, Alemtuzumab, N-Acetylcysteine, Celecoxib, Vitamin E, Alpha Lipoic Acid
Study Phase: Phase 2
MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders
MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders
Enrollment Status: Terminated
Publish Date: March 03, 2025
Intervention Type: Drug
Study Phase: Not Applicable
A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects ≤17 Years of Age With Cerebral Adrenoleukodystrophy (CALD)
A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects ≤17 Years of Age With Cerebral Adrenoleukodystrophy (CALD)
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Genetic
Study Drug: Elivaldogene Autotemcel
Study Phase: Phase 3
A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
Enrollment Status: Completed
Publish Date: April 25, 2022
Intervention Type: Genetic
Study Phase: Phase 2/Phase 3
A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in Males ≤17 Years of Age Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy
A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in Males ≤17 Years of Age Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy
Enrollment Status: Terminated
Publish Date: May 21, 2020
Intervention Type: Genetic
MT2011-21C Laronidase (Aldurazyme TM) Enzyme Replacement Therapy (ERT) With Hematopoietic Stem Cell Transplantation (HSCT) for Hurler Syndrome (MPS IH).
MT2011-21C Laronidase (Aldurazyme TM) Enzyme Replacement Therapy (ERT) With Hematopoietic Stem Cell Transplantation (HSCT) for Hurler Syndrome (MPS IH).
Enrollment Status: Terminated
Publish Date: September 27, 2018
Intervention Type: Drug
Early Diagnosis Of Childhood Cerebral Adrenoleukodystrophy
Early Diagnosis Of Childhood Cerebral Adrenoleukodystrophy
Enrollment Status: Withdrawn
Publish Date: July 06, 2018
View 6 Less Clinical Trials

207 Total Publications

Neurofilament light chain as a prognostic marker in cerebral adrenoleukodystrophy.
Neurofilament light chain as a prognostic marker in cerebral adrenoleukodystrophy.
Journal: Brain : a journal of neurology
Published: May 01, 2025
Similar Doctors
Experienced in Osteosclerosis Autosomal Dominant
Dr. Troy Lund
Hematology | Oncology
Experienced in Osteosclerosis Autosomal Dominant
Dr. Troy Lund
Hematology | Oncology

University Of Minnesota Masonic Children's Hospital

420 Delaware St SE, 
Minneapolis, MN 
 (0.4 miles away)
612-273-3000
Languages Spoken:
English
See accepted insurances

Troy Lund is a Hematologist and an Oncologist in Minneapolis, Minnesota. Dr. Lund is rated as a Distinguished provider by MediFind in the treatment of Osteosclerosis Autosomal Dominant. His top areas of expertise are Adrenoleukodystrophy (ALD), Alpha Mannosidosis, Aspartylglucosaminuria, Glucose-6-Phosphate Dehydrogenase Deficiency, and Bone Marrow Transplant.

Experienced in Osteosclerosis Autosomal Dominant
Dr. Jakub Tolar
Hematology | Oncology
Experienced in Osteosclerosis Autosomal Dominant
Dr. Jakub Tolar
Hematology | Oncology

University Of Minnesota Masonic Children's Hospital

420 Delaware St SE, 
Minneapolis, MN 
 (0.4 miles away)
612-273-2800
Languages Spoken:
English
See accepted insurances

Jakub Tolar is a Hematologist and an Oncologist in Minneapolis, Minnesota. Dr. Tolar is rated as a Distinguished provider by MediFind in the treatment of Osteosclerosis Autosomal Dominant. His top areas of expertise are Dyskeratosis Congenita, Fanconi Anemia, Congenital Aplastic Anemia, Bone Marrow Transplant, and Osteotomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Orchard's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 7 Advanced Conditions
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile